See more : Yuan Heng Gas Holdings Limited (0332.HK) Income Statement Analysis – Financial Results
Complete financial analysis of CONX Corp. (CONX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CONX Corp., a leading company in the Shell Companies industry within the Financial Services sector.
You may be interested
- MT Højgaard Holding A/S (MTHH.CO) Income Statement Analysis – Financial Results
- Iriso Electronics Co., Ltd. (6908.T) Income Statement Analysis – Financial Results
- Direct Communication Solutions, Inc. (DCSI.CN) Income Statement Analysis – Financial Results
- DiamondRock Hospitality Company (DRH) Income Statement Analysis – Financial Results
- Mayur Floorings Limited (MAYURFL.BO) Income Statement Analysis – Financial Results
CONX Corp. (CONX)
Industry: Shell Companies
Sector: Financial Services
About CONX Corp.
CONX Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses or assets. It intends to focus its search on identifying a prospective target operating in the technology, media, and telecommunications industries, including wireless communications industry. CONX Corp. was incorporated in 2020 and is based in Littleton, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 1.18K | 888.75K | 555.49K | 487.15 |
| Selling & Marketing | 1.18M | 0.00 | 0.00 | 161.89K |
| SG&A | 1.18M | 888.75K | 555.49K | 162.38K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 1.18M | 888.75K | 555.49K | 162.38K |
| Cost & Expenses | 1.18M | 888.75K | 555.49K | 162.38K |
| Interest Income | 267.48K | 4.94M | 75.01K | 5.34K |
| Interest Expense | 0.00 | 4.94M | 0.00 | 0.00 |
| Depreciation & Amortization | 167.90K | -21.36M | -19.86M | 5.34K |
| EBITDA | 0.00 | -888.75K | -20.41M | -162.38K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -1.18M | -888.75K | -555.49K | -162.38K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -4.75M | 26.30M | 19.93M | 2.28M |
| Income Before Tax | -5.93M | 25.41M | 19.37M | 2.12M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 65.47K | 1.21M | 18.45K | 1.12K |
| Net Income | -5.99M | 24.19M | 19.36M | 2.12M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.25 | 0.29 | 0.21 | 0.02 |
| EPS Diluted | -0.25 | 0.29 | 0.21 | 0.02 |
| Weighted Avg Shares Out | 23.80M | 82.98M | 93.77M | 93.76M |
| Weighted Avg Shares Out (Dil) | 23.80M | 82.98M | 93.77M | 93.76M |
Corgenix Announces Contract Manufacturing Agreement with EDP Biotech
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, announced today that it has entered into a contract manufacturing agreement with EDP Biotech, a medical device company focused on the development and commercialization...
Corgenix Announces Diagnostic Development Agreement with Lilly
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, announced today that it has entered into a collaboration agreement with Eli Lilly and Company (NYSE: LLY) to develop diagnostic technology in support of a...
Corgenix Reports Third Quarter Fiscal 2013 Financial Results
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, today filed its third quarter Form 10-Q and reported its financial results. The report disclosed that the company’s revenues for the quarter decreased slightly...
Corgenix Gains CE Mark for ReLASV® Antigen Rapid Test for Diagnosis of Lassa Fever
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic tests for cardiovascular disease, liver biomarkers and emerging pathogens and lethal viruses, today announced that notification of CE Mark was received for its ReLASV® Antigen Rapid...
Corgenix to Host Conference Call to Discuss Third Quarter Results
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Tuesday, May 14, 2013, at 4:00 p.m. EDT to discuss the Company’s financial and operating performance for its...
Corgenix Expands Contract Services Business Unit
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, and provider of contract services to the diagnostics, life sciences and pharmaceutical industries, today announced the expansion of its Contract Services business and the...
Corgenix Announces Initial Phase Completion of a Multi-Year Pivotal Clinical Trial of Rapid Test for Lassa Fever
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits for important cardiovascular and liver biomarkers as well as innovative products for emerging pathogens and lethal viruses, today announced completion of a major phase of...
Atherotech Diagnostics Lab Adds Corgenix AspirinWorks® Test for Aspirin Effect
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTCBB: CONX), a worldwide developer and marketer of diagnostic test kits, has announced that Atherotech Diagnostics Lab will carry its AspirinWorks® Test for determining aspirin effect. Under terms of the agreement, Corgenix’ AspirinWorks product will be...
Corgenix Reports Second Quarter Fiscal 2013 Financial Results
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, today filed its second quarter Form 10-Q and reported its financial results. The report disclosed that the company’s revenues increased both for the quarter...
Corgenix to Host Conference Call to Discuss Second Quarter Results
DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC BB: CONX), a worldwide developer and marketer of diagnostic test kits, will host a conference call on Thursday, February 14, 2013, at 4:00 p.m. EST to discuss the Company’s financial and operating performance for its...
Source: https://incomestatements.info
Category: Stock Reports